Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Blood (2022) 140 (Supplement 1): 10185–10188.

https://doi.org/10.1182/blood-2022-162336

Published: 2022

Journal Articles

Ninreal - a Real World (RW) Comparison of Ixazomib Triplets and IMiD Duplets, in Relapsed and Refractory Multiple Myeloma (RRMM) from the Austrian Myeloma Registry (AMR)

Wolfgang Willenbacher, Petra Pichler, Irene Strassl, Maria-Theresa Krauth, Hermine Agis, Siegfried Sormann, Bernd L. Hartmann, Klaus Podar, Roman Weger, Ella Willenbacher

Blood (2022) 140 (Supplement 1): 13194–13195.

https://doi.org/10.1182/blood-2022-165366

Published: 2022

Journal Articles

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Blood (2021) 138 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2021-150311

Published: 2021

Journal Articles

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-137447

Published: 2020

Journal Articles

Local Activator and T Cell Engager (αBCMA x αPD-L1 x αCD3) with Enhanced Tumor Killing and Minimal Cytokine Release for the Treatment of Multiple Myeloma

Melissa Vrohlings, Stephanie Jungmichel, Jan Müller, David Senn, Thomas Schleier, Fabian Scheifele, Severin Wendelspiess, Christian Leisner, Maria-Theresa Krauth, MD, Ulrich Jaeger, MD, Leonardo J. Borras

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-136648

Published: 2020

Journal Articles

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140918

Published: 2020

Journal Articles

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Blood (2020) 136 (Supplement 1): 27–29.

https://doi.org/10.1182/blood-2020-140701

Published: 2020

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Mathias A. Schneeweiss, Greiner Georg, MD PhD, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, MD, Friedrich Wimazal, MD, Corinna Steinhauser, Renate Thalhammer, MD, Ilse Schwarzinger, MD, Harald Esterbauer, MD PhD, Manuela Födinger, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2019) 134 (Supplement_1): 4269.

https://doi.org/10.1182/blood-2019-123390

Published: 2019

Journal Articles

Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

Georg Jeryczynski, MD, Antonia Eder, Eva-Maria Reitter, MD, Maria-Theresa Krauth, MD, Hermine Agis, MD

Blood (2019) 134 (Supplement_1): 3123.

https://doi.org/10.1182/blood-2019-124681

Published: 2019

Journal Articles

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Heinz Gisslinger, Bettina Gisslinger, Martin Schalling, MSc, Kurt Krejcy, PhD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, PhD, Maria-Theresa Krauth, MD

Blood (2018) 132 (Supplement 1): 3029.

https://doi.org/10.1182/blood-2018-99-119268

Published: 2018

Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Blood (2018) 132 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2018-99-118584

Published: 2018

Journal Articles

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Blood (2018) 132 (Supplement 1): 1960.

https://doi.org/10.1182/blood-2018-99-112155

Published: 2018

Journal Articles

Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study

Daniel Lechner, MD, Richard Greil, MD, Bernd Hartmann, Maria-Theresa Krauth, MD, Heinz Gisslinger, Ursula Vogl, Leopold Ohler, Hildegard T. Greinix, MD, Siegfried Sormann, Johannes Andel, Ernst Rechberger, Hermine Agis, MD

Blood (2018) 132 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2018-99-116292

Published: 2018

Journal Articles

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Blood (2018) 132 (7): 694–706.

https://doi.org/10.1182/blood-2017-10-810739

Published: 2018

Includes: Supplemental data

Journal Articles

Multiple Myeloma and Renal Impairment: Analysis of Induction Therapy Strategies and Outcome after Autologous Stem Cell Transplantation

Thomas Reiter, MD, Marlies Antlanger, Alexandra Böhm, Wolfgang Lamm, Max Gornicec, Ella Willenbacher, MD, David Nachbauer, Werner Rabitsch, Daniel Lechner, MD, Hildegard Greinix, Felix Keil, MD, Heinz Gisslinger, Hermine Agis, MD, Maria-Theresa Krauth, MD

Blood (2017) 130 (Supplement 1): 5424.

https://doi.org/10.1182/blood.V130.Suppl_1.5424.5424

Published: 2017

Journal Articles

Longitudinal Evaluation of Renal Function in Multiple Myeloma

Marlies Antlanger, Thomas Reiter, MD, Eleonore Pablik, Christoph Minichsdorfer, Edit Porpaczy, MD, Susanne Rasoul-Rockenschaub, Heinz Gisslinger, Hermine Agis, MD, Maria-Theresa Krauth, MD

Blood (2017) 130 (Supplement 1): 5387.

https://doi.org/10.1182/blood.V130.Suppl_1.5387.5387

Published: 2017

Journal Articles

Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data

Martin Schalling, Andreas Gleiss, Bettina Gisslinger, Albert Wölfler, Veronika Buxhofer-Ausch, Georg Jeryczynski, MD, Maria-Theresa Krauth, MD, Ingrid Simonitsch-Klupp, MD, Christine Beham-Schmid, Jurgen Thiele, Heinz Gisslinger

Blood (2017) 130 (Supplement 1): 4201.

https://doi.org/10.1182/blood.V130.Suppl_1.4201.4201

Published: 2017

Journal Articles

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Blood (2017) 130 (Supplement 1): 1643.

https://doi.org/10.1182/blood.V130.Suppl_1.1643.1643

Published: 2017

Journal Articles

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

Georg Jeryczynski, MD, Bettina Gisslinger, Martin Schalling, Maria Theresa Krauth, MD, Leonhard Muellauer, MD, Ana-Iris Schiefer, MD, Christoph Kornauth, MD, Ingrid Simonitsch-Klupp, MD, Jürgen Thiele, MD PhD, Heinz Gisslinger

Blood (2016) 128 (22): 4252.

https://doi.org/10.1182/blood.V128.22.4252.4252

Published: 2016

NARROW

Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Ninreal - a Real World (RW) Comparison of Ixazomib Triplets and IMiD Duplets, in Relapsed and Refractory Multiple Myeloma (RRMM) from the Austrian Myeloma Registry (AMR)

Composition of the Immune Environment at Baseline Correlates with Time to Response and Treatment Outcome in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (MM) Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Observation (AGMT_MM 02 Study)

Overexpression of PD-L1 Correlates with JAK2 -V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN

Local Activator and T Cell Engager (αBCMA x αPD-L1 x αCD3) with Enhanced Tumor Killing and Minimal Cytokine Release for the Treatment of Multiple Myeloma

Immunophenotyping of Baseline Bone Marrow Reveals a Specific Pattern of Immune Cells Associated with Greater Depth and Sustained Response in Newly Diagnosed Patients Randomized to Krd or Ktd Followed By Carfilzomib Maintenance or Control (AGMT MM 02 Study)

Quality of Life in Newly Diagnosed Patients with Multiple Myeloma Randomized to Either Krd or Ktd Induction Therapy Followed By Carfilzomib Maintenance or Control (AGMT MM 02 trial)

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Impact of HFE gene Variants on Iron Overload, Overall Survival and Leukemia-Free Survival in Myelodysplastic Syndromes

Firstline Daratumumab Shows High Hematologic and Organ Response Rates in Advanced Cardiac AL Amyloidosis - a Retrospective Case Series

Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone - Results from the Phase 3 Optimismm Study

Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Analysis of Real World Data from an Ongoing, National, Multi-Center, Non-Interventional Study

Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy

Multiple Myeloma and Renal Impairment: Analysis of Induction Therapy Strategies and Outcome after Autologous Stem Cell Transplantation

Longitudinal Evaluation of Renal Function in Multiple Myeloma

Essential Thrombocythemia Versus Pre-Fibrotic/Early Primary Myelofibrosis: Discrimination By Laboratory and Clinical Data

JAK2-Inhibitor Therapy Associated Lymphomas in Myelofibrosis: Distinct Clinico-Pathological Features Recapitulated in a Mouse Model

Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only